All In Biotech

Drug Trial Radar · NCT06141460

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

A Phase I/IIa, Dose-escalation and Dose-extension Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Nov 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Dec 12, 2023

Primary completion

Apr 15, 2026

Study completion Dec 31, 2030

Sponsor

Sponsor type
Industry
First posted
Nov 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I/IIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • RRG001Drug

    Administered via Subretinal injection. Dosage form: injection solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Eye Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.